Drug intelligence / Profile preview

losartan + s-amlodipine

Development stage
Unknown
Lead developer
Hanmi Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

**losartan + s-amlodipine** is a fixed-dose oral combination antihypertensive agent containing two drugs: **losartan** (an angiotensin II receptor blocker, ARB) and **S-amlodipine** (the S-enantiomer of amlodipine, a dihydropyridine calcium channel blocker, CCB). **Losartan** selectively blocks the angiotensin II type 1 receptor, inhibiting vasoconstriction and aldosterone-mediated volume expansion, thereby lowering blood pressure. **S-amlodipine** blocks L-type calcium channels in vascular smooth muscle, leading to vasodilation. This combination is used in the management of **hypertension** and reduces stroke risk, especially in patients with left ventricular hypertrophy. It is generally reserved for adults and indicated when monotherapy does not sufficiently control blood pressure[1][2][3][4][6].

Brand names
Losar-AAmlokind-LMNusar-AMRepace AFEslo TanTozamAsomex-LTZilos-AMCovamloLosacar-A
Other names
losartan s-amlodipinelosartan amlodipinelosartan + amlodipinelosartan/amlodipine
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on losartan + s-amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan + s-amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call